Inclusion Criteria:

1. All patients must give written informed consent

2. Patients should have pathologically or cytologically confirmed non-small cell lung
cancer with clinical or radiological evidence that it is not amenable to therapy with
curative intent

3. Patients should be potential candidates for therapy with an EGFR tyrosine kinase
inhibitor or with an anti-EGFR monoclonal antibody by clinical criteria.

4. Patients should have clinical characteristics that would suggest an increased
probability of benefit from an EGFR inhibitor. Specifically, they should have either:
"Less than a 10 pack-year smoking history AND a latency period from last tobacco use
to diagnosis of longer than 10 years AND either lung adenocarcinoma or NSCLC not
otherwise specified, OR "Known EGFR mutations OR high EGFR gene copy number"

5. Patients should have at least one tumor deposit that is > 1.0 cm in diameter, and
that is amenable to imaging

6. Patients should be ECOG performance status 0-2

7. Patients with brain metastases are eligible provided they meet all other eligibility
criteria and do not require corticosteroids or enzyme-inducing anticonvulsants and
provided it is felt clinically that they will not require radiotherapy in the three
(3) weeks subsequent to their participation in the study

8. Women of childbearing potential must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation. Childbearing potential will be defined as women who
have had menses within the past 12 months, who have not had tubal ligation or
bilateral oophorectomy. Should a woman become pregnant or suspect that she is
pregnant while participating in this study, she should inform her treating physician
immediately. The patient, if a man, agrees to use effective contraception or
abstinence

9. The patient must be considered legally capable of providing his or her own consent
for participation in this study

10. Subjects must be at least 18 years of age

Exclusion Criteria:

1. Prior therapy with an EGFR inhibitor or an anti-EGFR monoclonal antibody

2. Radiotherapy, chemotherapy or any investigational agent within the previous 4 weeks
of administrating 18F-PEG6-IPQA for PET/CT imaging.

3. A non-investigational targeted agent within the previous 2 weeks of 18F-PEG6-IPQA for
PET/CT imaging.

4. Thoracic or abdominal surgery within the previous 2 weeks of 18F-PEG6-IPQA for PET/CT
imaging.

5. A tumor that is known to have a K-ras mutation

6. Squamous cell, large cell undifferentiated, neuroendocrine or small cell
undifferentiated carcinoma of the lung

7. A known other currently active malignancy. (Benign tumors and benign polyps, basal
cell carcinomas of skin, superficial papillary bladder tumors, and pre-invasive
carcinoma of the cervix are permitted)

8. Physical inability to undergo a scanning procedure (e.g., inability to lie flat for
the required period of time - three sessions of roughly an hour each with ten
minutes' rest in between)

9. Serum creatinine >1.5 x ULN, bilirubin >1.5 x ULN, AST > 3 x ULN

10. 10. Hemoglobin < 8 g/dL, absolute neutrophil count < 1,500/mm3, platelet count
<100,000/mm3

11. Potentially life-threatening arrhythmia; myocardial infarct within the previous 3
months; unstable angina, or angina at rest; congestive heart failure (New York Heart
Association Functional Classification class II or worse), uncontrolled hypertension
(systolic BP > 160 or diastolic BP >100).

12. Active acute infection (i.e. currently treated with antibiotics). Patients with
chronic infections such as hepatitis B or C, mycobacterium avium or similar
infections will be eligible provided they meet all other eligibility criteria.

13. Oxygen saturation <90% on room air

14. Clinical requirement for systemic corticosteroids for control of cerebral edema or
for enzyme-inducing anticonvulsants. (Inhaled steroids and systemic steroids for COPD
are permitted).

15. Pregnant or nursing

16. Any condition that is unstable or could jeopardize the safety of the patient and his
or her compliance in the study, in the investigator's judgment